Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 22;4(8):1071–1083. doi: 10.1038/s42255-022-00617-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a–h, i.p. GTT in 34-week-old male naïve DIO mice 6 h after treatment with a single s.c. dose of tesaglitazar (10 (a) or 100 nmol kg⁻¹ (b)), or with the GLP-1RA or GLP-1RA/tesaglitazar at a dose of 100 nmol kg⁻¹ (c,d), 10 nmol kg⁻¹ (e,f) or 3 nmol kg⁻¹ (g,h). i–n, i.p. GTT in 27–29-week-old male DIO mice 6 h after single s.c. treatment at doses of 0.5 nmol kg⁻¹ (i,j), 5 nmol kg⁻¹ (k,l) or 50 nmol kg⁻¹ (m,n). In a–h, sample sizes are n = 8 mice each treatment group. In i–n, sample sizes for treatment with Vhcl, GLP-1RA, GLP-1RA + tesaglitazar and GLP-1RA/tesaglitazar are n = 8/8/8/7 mice (i,j,m,n), n = 8/8/8/8 mice (k) and n = 8/8/7/7 mice (l). Data represent means ± s.e.m. Data in a, c, e, g, I, k and m have been analysed by two-way ANOVA with Bonferroni post hoc comparison for individual time points. Data in b, d, f, h, j, l and n have been analysed by one-way ANOVA using Bonferroni’s multiple comparison test. Asterisks indicate *P < 0.05, **P < 0.01, ***P < 0.001. Black asterisks indicate comparison to Vhcl, red asterisks indicate comparison to GLP-1RA, blue asterisks indicate comparison to the GLP-1RA + tesaglitazar cotherapy. Exact P values for treatment effects are b P = 0.0199; c both P < 0.0001; d both P < 0.0001; e P = 0.0056, P < 0.0001 and P < 0.0001; f both P < 0.0001; g both P < 0.0001; h both P < 0.0001; i all P < 0.0001; j P = 0.0021 (black asterisks), P = 0.0027 (red asterisks), P = 0.0003 (blue asterisks); k P = 0.0011 (red asterisks), P < 0.0001 (blue asterisks) and P < 0.0001 (black asterisks); l P = 0.0388 (red asterisks), P = 0.0002 (blue asterisks), P < 0.0001 (Vhcl versus all other groups); m P = 0.0036 (red asterisks), P < 0.0001 (black asterisks); n P = 0.0229, P = 0.0002 (Vhcl versus GLP-1RA + tesaglitazar), P < 0.0001 (Vhcl versus GLP-1RA/tesaglitazar). For exact P values at individual time points (b,e,g,i,k,m), see the data source file.

Source data